George Padron Specialty Medicine, ID & Vaccines, Clinical Trial Updates | Jul 10, 2026 A phase 3 trial finds the two-drug doravirine-islatravir tablet noninferior to bictegravir-emtricitabine-tenofovir for initial HIV-1 treatment at 48 weeks.
George Padron Healthcare Headlines, ID & Vaccines | Jun 23, 2026 A VISION-network study finds the 2024-2025 COVID vaccines were 35% effective against hospitalization and 41% against critical illness in adults, waning over time.
George Padron Specialty Medicine, ID & Vaccines, Population Health Management | Jun 17, 2026 An FDA panel voted 9-0 for Moderna's mFlusiva, the first US mRNA flu vaccine. A decision is due Aug. 5, but contracting timing pushes plan uptake to H2 2027.
Sonia Reyes Specialty Medicine, Healthcare Headlines, ID & Vaccines | May 18, 2026 Two unrelated outbreaks, Bundibugyo Ebola in eastern DRC and Andes hantavirus from an Argentine cruise, show surveillance gaps that matter for direct managed care.
Sonia Reyes Specialty Medicine, Healthcare Headlines, ID & Vaccines | May 14, 2026 NYT reported that AI-generated images, videos, and case maps are fueling rapid misinformation around the hantavirus outbreak, raising new operational challenges for public health communication.
🔎︎
